T-knife Therapeutics Presents Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting Demonstrating a Potential Best-in-Class PRAME Targeted TCR-T Therapy– TK-6302, a supercharged PRAME targeting TCR-T therapy, demonstrates best-in-class preclinical anti-tumor efficacy as compared to current clinical stage PRAME TCR-T approaches, providing the potential for broad, deep and durable responses in hard-to-treat solid tumor indications
T-knife Therapeutics Announces Five Presentations at American Association for Cancer Research (AACR) Annual MeetingSAN FRANCISCO and BERLIN, March 25, 2025 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer, today announced that five abstracts highlighting its PRAME-targeted TCR-T therapy, TK-6302, and its platform technologies will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place from April 25-30, 2025 in Chicago, IL.
T-knife Therapeutics Welcomes Dr. Sophie Papa to its Board of DirectorsSAN FRANCISCO and BERLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer, today announced the appointment of Sophie Papa, FRCP, Ph.D., to its Board of Directors.
T-knife Therapeutics to Participate in Two Investor Conferences in MarchSAN FRANCISCO and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer, today announced that members of the company’s management team will participate in two investor conferences in March.
T-knife Therapeutics Announces the Appointment of Simone Silva Steiner, Ph.D., as Chief Technical Operations OfficerSAN FRANCISCO and BERLIN, Nov. 06, 2023 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver transformational benefits to cancer patients, today announced the appointment of Simone Silva Steiner, Ph.D., to the role of Chief Technical Operations Officer.
T-knife Therapeutics Announces Four Presentations at the Upcoming Society for Immunotherapy of Cancer (SITC) Annual MeetingSAN FRANCISCO and BERLIN, Sept. 27, 2023 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver transformational benefits to cancer patients, today announced four poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting which will take place November 1-5, 2023 in San Diego, CA.
T-knife Therapeutics Presents Preclinical Data on the Anti-Tumor Activity of TK-8001 at ISCT Annual MeetingSAN FRANCISCO and BERLIN, June 01, 2023 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver transformational benefits to cancer patients, today announced presentation of a poster titled, “MAGE-A1 targeting TK-8001 TCR-T cells currently being investigated in the IMAG1NE Phase 1/2 clinical trial demonstrate broad in vitro and in vivo anti-tumor activity and are superior to human-derived MAGE-A1 TCRs” at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting being held from May 31 – June 3, 2023 in Paris, France.
T-knife Therapeutics Announces the Appointment of Behzad Kharabi, M.D., as Chief Medical OfficerSAN FRANCISCO and BERLIN, Feb. 08, 2023 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver transformational benefits to cancer patients, today announced it has appointed Behzad Kharabi Masouleh, M.D., as Chief Medical Officer.
T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical TrialSAN FRANCISCO and BERLIN, Oct. 20, 2022 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver transformational benefits to cancer patients, today announced it has dosed the first patient in the IMAG1NE Phase 1/2 clinical trial. The IMAG1NE trial is designed to evaluate the safety and preliminary efficacy of TK-8001, a T cell receptor (TCR) engineered T cell therapy (TCR-T) specific for the Melanoma-associated Antigen Gene-A1 (MAGE-A1), in patients with solid tumors.
